Gujarat Themis Biosyn Ltd Multibagger 2022 Analysis
About Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with GIIC Ltd. and Chemosyn (P) Ltd. It commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies – Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is being actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007.
Incorporated in 1981 as a joint sector company with GIIC Ltd. and Chemosyn (P) Ltd. Commenced production in August, 1985 by producing Erythromycin and Erythromycin salts and formulations. The Company was taken over during June 1991 by Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug Companies – Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd.. The Company entered into Technical & Financial collaboration with Yuhan Corporation, South Korea. With Yuhan’s know-how, GTBL became India’s first Company to start commercial production of Anti-tuberculosis drug Rifampicin.
Products & Services
- Rifamycin-S an intermediate for “Rifampicin” on treatment of Tuberculosis (TB)
Profit & loss
Warren Buffett Checklist
- Upgrade from Contract Manufacturer to Manufacturer to Multiplier Companies & Having Strong Sales, Profit & EPS Growth
- Company is debt free
- CAGR 20% Growth visible for past 5 years
- Intrinsic Value Discount is 70%
- Stock is trading at 7X of book value
As per the Expansion & Value Investing grounds the company is having Multibagger Properties.
Logos are Copyright of respective owners. The advice or opinions here is not for public distribution and has been furnished to you solely for your information purpose and must not be reproduced or redistributed to any other person. Any report is created from Public Source of Information available through Interne
t from Company website & Other websites & the Research Analyst does not guarantee the Validation of Content in this report.
FREE Multibagger Stocks for 2025
Multibagger with Expansion Plans | Low PE Ratio | Low Book Value Ratio | Intrinsic Value Discount 70 % | PLUS Free Value Investing Education